DOCSLIB.ORG

FOI 218-1314 Document 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FOI 218-1314 Document 1 Name Form Dosage Riboflavin 0.1% in 20% dextran - Medio Cross eye drops As per literature Riboflavin 0.1% in 20% dextran - Medio Cross eye drops As per literature Midodrine tablet Up to 5mg daily, orally Dimethyl sulfoxide (DMSO) - Rimso-50 solution 50mL of 50% solution intravesically (for fifteen minutes), weekly Dimethyl sulfoxide (DMSO) - Rimso-50 solution 50mL of 50% solution intravesically (for fifteen minutes), weekly Buspirone Hydrochloride tablet As per protocol Ergocalciferol - Sterogyl injection 600,000 IU six monthly Cholecalciferol injection 300,000IU 3 monthly Paromomycin tablet 160mg three times daily Furazolidone oral application 100mg twice daily, orally Bismuth Subcitrate - Denol oral application 240mg twice daily Febuxostat - Uloric tablet 40mg daily, orally Tacrolimus 0.03% - Protopic ointment Apply topically twice daily Melatonin capsule 3mg at night Cinnarizine - Stugeron tablet 25mg three times daily Adalimumab - Humira injection As per protocol Triamcinolone - Triesence injection As per literature via intravitreal injection Bismuth Subcitrate - Denol tablet 240mg twice daily Bismuth Subcitrate - Denol tablet 240mg twice daily Tetracycline capsule 250mg capsule, two capsules four times daily Levofloxacin tablet 500mg twice daily Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Midodrine tablet 10mg daily, orally Melatonin oral application 3mg at night Triamcinolone - Triesence injection As per literature via intravitreal injection Paromomycin capsule 250mg capsule, three capsules three times daily Paromomycin capsule 250mg capsule, three capsules three times daily Mexiletine - Mexitil tablet As per protocol Riboflavin - Ricrolin eye drops As per literature Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per Literature Bismuth Subcitrate - Denol tablet 120mg four times daily Ranibizumab - Lucentis injection As per protocol Diflunisal tablet 250mg twice daily, orally 68-Gallium DOTATATE injection 150MBq 68-Gallium DOTATATE injection 150MBq 68-Gallium DOTATATE injection 150MBq 68-Gallium DOTATATE injection 150MBq 68-Gallium DOTATATE injection 150MBq 68-Gallium DOTATATE injection 150MBq Midodrine tablet 5mg three times daily, orally (as tolerated) Timolol (preservative free) eye drops One drop twice daily Bismuth Subcitrate - Denol tablet 120mg four times daily Tetracycline oral application 500mg four times daily Triamcinolone - Triesence injection As per literature via intravitreal injection Mexiletine - Mexitil capsule 250mg twice daily, orally Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature via intravitreal injection Levofloxacin tablet 500mg twice daily Levofloxacin tablet 500mg twice daily Technetium-99m (Tc-99M) - Mebrofenin injection 200MBq by intravenous infusion Levofloxacin tablet 500mg twice daily Iloprost injection, intravenous infusion Up to 2nanograms/kg/min for six hours daily by intravenous infusion Iloprost injection, intravenous infusion Up to 2nanograms/kg/min for six hours daily by intravenous infusion Triamcinolone - Triesence injection As per literature by intraocular injection; requested 2x 2mg/0.05mL Triamcinolone - Triesence injection As per literature via intravitreal injection Triamcinolone - Triesence injection As per literature by intravitreal injection; requested 2x2mg/0.05mL Furazolidone - Furasian tablet 100mg four times daily Tetracycline capsule 500mg four times daily Calcitriol - Rolcatrol oral liquid 0.1mcg once daily Allergen - Multiple Skin Prick Test As per manufacturer's protocol Iloprost injection Up to 2ng/kg/min for six hours daily by intravenous infusion Cinnarizine - Stugeron tablet 25mg once daily Triamcinolone - Triesence injection As per literature by intravitreal injection, requested 4mg/0.1 mL Melatonin oral application Maximum of 5mg at night abatacept - Orencia powder 750mg daily Triamcinolone - Triesence injection As per literature by intravitreal injection, requested 4mg/0.1mL. abatacept - Orencia powder 750mg daily abatacept - Orencia powder 750mg daily Bismuth Subcitrate - Denol tablet 120mg four times daily Bifidobacterium infantis & Lactobacillus acidophilus - capsule One capsule once daily Infloran Flunarizine - Sibelium tablet Maximum of 10mg at night Bifidobacterium infantis & Lactobacillus acidophilus - capsule Maximum of one capsule once daily Infloran Riboflavin 0.1% in 20% dextran - Medio Cross eye drops As per literature Deflazacort - Calcort tablet 30mg daily, orally Paromomycin oral application 2000mg daily Travoprost - Travatan Z eye drops One drop at night, both eyes Tizanidine oral application 2mg twice daily Pipothiazine - Piportil injection 100mg 2 weekly Iloprost injection, intravenous infusion Up to 2ng/kg/min for six hours daily by intravenous infusion Bismuth Subcitrate - Denol tablet 120mg four times daily Tetracycline tablet 250mg four times daily Dexamethasone - Minims (Dexamethasone) eye drops One drop to left eye; ten times daily Riboflavin 0.1% in 20% dextran - Medio Cross eye drops As per literature Dihydroergotamine tablet 2.5-10mg three times daily, orally Riboflavin 0.1% - Opto Ribolink Hypertonic Solution eye drops As per literature Triamcinolone - Triesence injection As per literature via intravitreal injection Bismuth Subcitrate - Denol tablet 120mg four times daily Cisapride - Prepulsid oral application Maximum of 20mg twice daily Triamcinolone - Triesence injection As per literature via intravitreal injection Bismuth Iodoform & Paraffin Paste (BIPP) paste One unit topically as per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% in 20% dextran - Medio Cross eye drops As per protocol Dexamethasone - Minims (Dexamethasone) eye drops One drop to eye four times daily initially Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Triamcinolone - Triesence injection As per literature via intravitreal injection Biotin tablet As per protocol Triamcinolone - Triesence injection As per literature by intravitreal injection Cinnarizine - Stugeron tablet 25mg three times daily Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Doxycycline I/V injection 100mg (10mg/mL) injected intralesionally Dexamethasone - Minims (Dexamethasone) eye drops One drop to left eye eight times dailiy Midodrine tablet 10mg in the morning, orally Bismuth Subcitrate - Denol tablet 120mg four times daily Tetracycline capsule 500mg four times daily Deflazacort - Calcort tablet 45mg daily, orally Melatonin capsule Up to 6mg at night Betaxolol Hydrochloride - Betoptic-S eye drops One drop both eyes daily 68-Gallium DOTATATE injection 150MBq Buspirone Hydrochloride tablet 300mg daily Triamcinolone - Triesence injection As per literature via intravitreal injection Cyclosporin Ophthalmic Emulsion 0.05% - Restasis eye drops Apply topically, one drop twice daily as per protocol Cisapride - Prepulsid tablet 20mg twice daily Midodrine tablet 5-10mg three times daily, orally Ruxolitinib tablet 20mg twice daily Triamcinolone - Triesence injection As per literature via intravitreal injection Tacrolimus 0.03% - Protopic ointment Apply as per literature Iloprost injection 60micrograms daily by intravenous infusion Levofloxacin tablet 500md twice daily Pimozide - Orap tablet 1mg orally, daily Riboflavin 0.1% - Opto Ribolink eye drops As per literature Bismuth Subcitrate - Denol tablet 240mg twice daily Melatonin tablet Up to 6mg at night Furazolidone oral application 100mg twice daily Bismuth Subcitrate - Denol tablet 240mg twice daily Triamcinolone - Triesence injection As per literature via intravitreal injection Tetracycline capsule 500mg four times daily Bismuth Subcitrate - Denol tablet 120mg four times daily Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Riboflavin 0.1% - Opto Ribolink eye drops As per protocol Triamcinolone - Triesence injection As per literature via intravitreal injection Cinnarizine - Stugeron tablet 25mg three times daily Sodium Chloride Hypertonic Ophthalmic Solution 5% - eye drops Two drops twice daily, right eye Muro 128 5% Cisapride - Prepulsid tablet 50mg daily Iloprost injection Up to 2ng/kg/min for six hours daily by intravenous infusion Pristinamycin tablet 500mg three times daily Cisapride - Prepulsid oral application 10mg three times daily Yttrium Citrate injection 250MBq Thalidomide tablet 50mg tablets, two tablets weekly Calcium Carboxymethyl Zinc - Ilex cream Apply topically as per literature Doxycycline
Load more

Recommended publications
  • Dimethyl Sulfoxide MSDS
    He a lt h 1 2 Fire 2 2 0 Re a c t iv it y 0 Pe rs o n a l Pro t e c t io n F Material Safety Data Sheet Dimethyl sulfoxide MSDS Section 1: Chemical Product and Company Identification Product Name: Dimethyl sulfoxide Contact Information: Catalog Codes: SLD3139, SLD1015 Sciencelab.com, Inc. 14025 Smith Rd. CAS#: 67-68-5 Houston, Texas 77396 RTECS: PV6210000 US Sales: 1-800-901-7247 International Sales: 1-281-441-4400 TSCA: TSCA 8(b) inventory: Dimethyl sulfoxide Order Online: ScienceLab.com CI#: Not applicable. CHEMTREC (24HR Emergency Telephone), call: Synonym: Methyl Sulfoxide; DMSO 1-800-424-9300 Chemical Name: Dimethyl Sulfoxide International CHEMTREC, call: 1-703-527-3887 Chemical Formula: (CH3)2SO For non-emergency assistance, call: 1-281-441-4400 Section 2: Composition and Information on Ingredients Composition: Name CAS # % by Weight Dimethyl sulfoxide 67-68-5 100 Toxicological Data on Ingredients: Dimethyl sulfoxide: ORAL (LD50): Acute: 14500 mg/kg [Rat]. 7920 mg/kg [Mouse]. DERMAL (LD50): Acute: 40000 mg/kg [Rat]. Section 3: Hazards Identification Potential Acute Health Effects: Slightly hazardous in case of inhalation (lung irritant). Slightly hazardous in case of skin contact (irritant, permeator), of eye contact (irritant), of ingestion, . Potential Chronic Health Effects: Slightly hazardous in case of skin contact (irritant, sensitizer, permeator), of ingestion. CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance may be toxic to blood, kidneys, liver, mucous membranes, skin, eyes.
    [Show full text]
  • PET Imaging of Occult Tumours by Temporal Integration of Tumour-Acidosis Signals from Ph-Sensitive 64Cu-Labelled Polymers
    ARTICLES https://doi.org/10.1038/s41551-019-0416-1 PET imaging of occult tumours by temporal integration of tumour-acidosis signals from pH-sensitive 64Cu-labelled polymers Gang Huang 1, Tian Zhao1, Chensu Wang 1, Kien Nham2, Yahong Xiong2, Xiaofei Gao3, Yihui Wang3, Guiyang Hao 2, Woo-Ping Ge3, Xiankai Sun2, Baran D. Sumer 4* and Jinming Gao 1,4* Owing to the diversity of cancer types and the spatiotemporal heterogeneity of tumour signals, high-resolution imaging of occult malignancy is challenging. 18F-fluorodeoxyglucose positron emission tomography allows for near-universal cancer detec- tion, yet in many clinical scenarios it is hampered by false positives. Here, we report a method for the amplification of imaging contrast in tumours via the temporal integration of the imaging signals triggered by tumour acidosis. This method exploits the catastrophic disassembly, at the acidic pH of the tumour milieu, of pH-sensitive positron-emitting neutral copolymer micelles into polycationic polymers, which are then internalized and retained by the cancer cells. Positron emission tomography imaging of the 64Cu-labelled polymers detected small occult tumours (10–20 mm3) in the brain, head, neck and breast of mice at much higher contrast than 18F-fluorodeoxyglucose, 11C-methionine and pH-insensitive 64Cu-labelled nanoparticles. We also show that the pH-sensitive probes reduce false positive detection rates in a mouse model of non-cancerous lipopolysaccharide-induced inflammation. This macromolecular strategy for integrating tumour acidosis should enable improved cancer detection, surveil- lance and staging. ancer exhibits diverse genetic and histological differences tumours over the surrounding normal tissues often leads to false from normal tissues1.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study
    A Technique for Standardized Central Analysis of 6-18F-Fluoro-L-DOPA PET Data from a Multicenter Study Alan L. Whone, MRCP1; Dale L. Bailey, PhD2; Philippe Remy, PhD3; Nicola Pavese, MD1; and David J. Brooks, DSc1 1Division of Neuroscience and MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom; 2Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia; and 3CEA-Centre National de la Recherche Scientifique Unite´ de Recherche Associe´e 2210, Service Hospitalier Frederic Joliot, Orsay, France tralized analysis offers the potential for improved detection of We have recently completed a large 6-18F-fluoro-L-DOPA (18F- outcomes due to the standardization of the analytic approach DOPA) PET study comparing rates of loss of dopamine terminal and allows the analysis of large numbers of PET studies. function in Parkinson’s disease (PD) patients taking either the Key Words: PET; 18F-DOPA; Parkinson’s disease; progression; dopamine agonist ropinirole or L-DOPA. This trial involved a central analysis “distributed acquisition/centralized analysis” method, in which J Nucl Med 2004; 45:1135–1145 18F-DOPA images were acquired at 6 different PET centers around the world and then analyzed at a single site. To our knowledge, this is the first time such a centralized approach has been employed with 18F-DOPA PET and this descriptive basic science article outlines the methods used. Methods: One hun- With rapid advances in molecular medicine, the pro- dred eighty-six PD patients were randomized (1:1) to ropinirole duction of neuroprotective or neurorestorative agents that or L-DOPA therapy, and 18F-DOPA PET was performed at base- affect the progression of degenerative conditions such as line and again at 2 y.
    [Show full text]
  • [123I]FP-CIT SPECT in Atypical Degenerative Parkinsonism
    CONTRAST AGENT EVALUATION [123I]FP-CIT SPECT in atypical degenerative parkinsonism One of the most widely used techniques to support the clinical diagnosis of Parkinson’s disease is the SPECT scan with [123I]FP-CIT. This tracer binds reversibly and visualizes the striatal presynaptic dopamine transporters. Several uncertainties remain on the value of [123I]FP-CIT and SPECT in atypical degenerative parkinsonian syndromes. In this concise review, we discuss the contribution of SPECT and [123I]FP-CIT in supporting the clinical diagnosis of Parkinson’s disease and their role in the differential diagnosis of Parkinson’s disease and atypical degenerative parkinsonism. The chemistry, pharmacodynamics and pharmacokinetics of [123I]FP-CIT are also discussed. 1,2,3 KEywordS: atypical degenerative parkinsonism n FP-CIT n ioflupane n SPECT Ioannis U Isaias* , Giorgio Marotta4, Gianni Pezzoli2, Parkinson’s disease (PD) is the second most dystonic tremor [15] and psychogenic parkin- Osama Sabri5 [1] [16,17] 5,6 common neurodegenerative disorder , yet sonism . In this concise review, we will & Swen Hesse 123 early accurate diagnosis remains challenging. discuss the role of SPECT and [ I]FP-CIT in 1Università degli Studi di Milano, The estimated prevalence of PD is 0.5–1% in supporting the clinical diagnosis of PD and its Dipartimento di Fisiologia Umana, those aged 65–69 years and 1–3% in those aged differential diagnosis with ADP. Milano, Italy 2Centro per la Malattia di Parkinson e i ≥80 years [1]. Although the clinical diagnosis of Disturbi del Movimento,
    [Show full text]
  • Synthesis, Characterization and Biological Evaluation of New Potentially Active Hydrazones of Naproxen Hydrazide
    Available online a t www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 2015, 7(10):93-101 (http://derpharmachemica.com/archive.html) ISSN 0975-413X CODEN (USA): PCHHAX Synthesis, characterization and biological evaluation of new potentially active hydrazones of naproxen hydrazide Ali H. Abbas 1, Amer N. Elias 2*and Ammar A. Fadhil 3 1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Tikrit, Salah-Aldin, Iraq 2Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq 3Department of Pharmacology and Toxicology, College of Pharmacy, University of Baghdad, Baghdad, Iraq _____________________________________________________________________________________________ ABSTRACT To synthesize new hydrazone derivatives of naproxen with enhanced anti-inflammatory activity and devoid the ulcerogenic side effects. Hydrazones were synthesized by conjugation of naproxen hydrazide with seven natural and synthetic aldehyde and ketone by using glacial acetic acid as catalyst. The synthesis has been carried out following simple methodology in excellent isolated yields.The structure of the synthesized derivatives has been characterized by elemental microanalysis (CHN), FTIR Spectroscopy, and other physicochemical properties.The anti- inflammatory activity of the synthesized compounds was evaluated in vivo using the egg-white induced edema model in rats, and the results of the biological assay was found to be comparable to Naproxen in this regard. The synthesizedhydrazone of
    [Show full text]
  • DICOM Conformance Template
    g GE Heathcare Technical Publications Direction 5507068-1EN (DOC1584283) Revision 1 DaTQUANT Application™ DICOM CONFORMANCE STATEMENT Copyright 2015 by General Electric Co. Do not duplicate g GE Heathcare LIST OF REVISIONS REV DATE DESCRIPTION PAGES APPR. 1 May 2015 Initial Release All M. Mesh DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 THIS PAGE LEFT INTENTIONALLY BLANK DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 CONFORMANCE STATEMENT OVERVIEW DaTQUANT application is an application that uses NM and CT images and creates NM, SC and MFSC images. Table 0.1 provides an overview of the network services supported by the DaTQUANT application. Table 0.1 – APPLICATION SOP Classes User of Object Creator of Instances Object Instances Transfer Secondary Capture Image Storage No Yes Multi-frame True Color Secondary Capture Image Storage No Yes Nuclear Medicine Image Storage Yes Yes Computerized Tomography Image Storage Yes No 4 DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 1. INTRODUCTION ............................................................................................................... 8 1.1 Overview ..................................................................................................................................................................... 8 1.2 Overall DICOM Conformance Statement Document Structure ..........................................................................
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Lettirs to Th Editor Radiation Injury from Interstitial Injection Of
    DEPARTMENTS Lettirs to th Editor Radiation Injury from Interstitial Injection of measuring approximately 2 cm x 1 cm. Monitoring of the site Iodine-131-Iodocholesterol demonstrated retention of 131!(Fig. 2). On the basis of serial counts, the half-time was 5.5 days at the i.v. injection site. TO THE EDITOR: A 44-yr-oldman wasinvestigatedfor recur The absorbeddose deliveredto the overlyingskin cannot be rent Cushing's disease. An adrenal gland scan was initiated with precisely calculated because it has a very strong inverse depend injection of 34-MBq of ‘31I-iodocholesterol over a 5-mm interval. ence on the interstitial volume occupied by the injectate, and this Prior to injection, blood was withdrawn into the hub of the volume is not accurately known. The absorbed dose can be syringe to ensure correct i.v. placement. At the conclusion of the estimated by treating the interstitial volume occupied by the injection, the patient volunteered that the injection had been the injectate as a disk of the same area as the erythematous patch; least painful i.v. entry he had experienced. Seven days later, the thickness of this volume can be roughly estimated. The imaging failed to detect any radioactivity in the field of view volumeofdistributionwasassumedto remainconstantovertime centered on the adrenal glands. Monitoring of the injection site since the injectate is not water-soluble. The absorbed dose in this demonstrated essentially complete retention of the radiophar volume can be calculated by the method of Johns and Cun maceutical at the site. ningham (1). Because the model assumes no activity outside the The patient returned 13 days later (i.e., 20 days after the volume,the absorbeddose in the regionadjacentto this volume injection) to inquire about the tender pruritic and erythematous within the range of the beta particles (i.e., the skin) can be patch at the injection site at which time the photograph in Figure estimated to be halfthe dose inside the volume.
    [Show full text]
  • Huidige Situatie En Toekomstverkenning
    Stichting Laka: Documentatie- en onderzoekscentrum kernenergie De Laka-bibliotheek The Laka-library Dit is een pdf van één van de publicaties in This is a PDF from one of the publications de bibliotheek van Stichting Laka, het in from the library of the Laka Foundation; the Amsterdam gevestigde documentatie- en Amsterdam-based documentation and onderzoekscentrum kernenergie. research centre on nuclear energy. Laka heeft een bibliotheek met ongeveer The Laka library consists of about 8,000 8000 boeken (waarvan een gedeelte dus ook books (of which a part is available as PDF), als pdf), duizenden kranten- en tijdschriften- thousands of newspaper clippings, hundreds artikelen, honderden tijdschriftentitels, of magazines, posters, video's and other posters, video’s en ander beeldmateriaal. material. Laka digitaliseert (oude) tijdschriften en Laka digitizes books and magazines from the boeken uit de internationale antikernenergie- international movement against nuclear beweging. power. De catalogus van de Laka-bibliotheek staat The catalogue of the Laka-library can be op onze site. De collectie bevat een grote found at our website. The collection also verzameling gedigitaliseerde tijdschriften uit contains a large number of digitized de Nederlandse antikernenergie-beweging en magazines from the Dutch anti-nuclear power een verzameling video's. movement and a video-section. Laka speelt met oa. haar informatie- Laka plays with, amongst others things, its voorziening een belangrijke rol in de information services, an important role in the Nederlandse anti-kernenergiebeweging. Dutch anti-nuclear movement. Appreciate our work? Feel free to make a small donation. Thank you. www.laka.org | [email protected] | Ketelhuisplein 43, 1054 RD Amsterdam | 020-6168294 | L.P.
    [Show full text]
  • Nuclear Pharmacy Quick Sample
    12614-01_CH01-rev3.qxd 10/25/11 10:56 AM Page 1 CHAPTER 1 Radioisotopes Distribution for Not 1 12614-01_CH01-rev3.qxd 10/25/1110:56AMPage2 2 N TABLE 1-1 Radiopharmaceuticals Used in Nuclear Medicine UCLEAR Chemical Form and Typical Dosage P Distribution a b HARMACY Radionuclide Dosage Form Use (Adult ) Route Carbon C 11 Carbon monoxide Cardiac: Blood volume measurement 60–100 mCi Inhalation Carbon C 11 Flumazenil injection Brain: Benzodiazepine receptor imaging 20–30 mCi IV Q UICK Carbon C 11 Methionine injection Neoplastic disease evaluation in brain 10–20 mCi IV R Carbon C 11 forRaclopride injection Brain: Dopamine D2 receptor imaging 10–15 mCi IV EFERENCE Carbon C 11 Sodium acetate injection Cardiac: Marker of oxidative metabolism 12–40 mCi IV Carbon C 14 Urea Diagnosis of Helicobacter pylori infection 1 µCi PO Chromium Cr 51 Sodium chromate injection Labeling red blood cells (RBCs) for mea- 10–80 µCi IV suring RBC volume, survival, and splenic sequestration Cobalt Co 57 Cyanocobalamin capsules Diagnosis of pernicious anemia and 0.5 µCi PO Not defects of intestinal absorption Fluorine F 18 Fludeoxyglucose injection Glucose utilization in brain, cardiac, and 10–15 mCi IV neoplastic disease Fluorine F 18 Fluorodopa injection Dopamine neuronal decarboxylase activity 4–6 mCi IV in brain Fluorine F 18 Sodium fluoride injection Bone imaging 10 mCi IV Gallium Ga 67 Gallium citrate injection Hodgkin’s disease, lymphoma 8–10 mCi IV Acute inflammatory lesions 5 mCi IV Indium In 111 Capromab pendetide Metastatic imaging in patients with biopsy-
    [Show full text]
  • Viiith INTERNATIONAL SYMPOSIUM on NUCLEAR MEDICINE
    INIS-mf--10949 VIIIth INTERNATIONAL SYMPOSIUM ON NUCLEAR MEDICINE JUNE 2 - 5, 1986 KARLOVY VARY CZECHOSLOVAKIA ABSTRACTS ABSTRACTS The booklet contains all abstracts of papers submitted in time to the Secretariat of the Symposium. The abstracts were reproduced from the original forms sent by the ithors. The responsibilit >r the contents and gram- matical style the. re lies upon the authors. 17 ANTIBODY GUIDED TUMOR DETECTION IN PATIENTS WITH CARCINOMA. P.Riva.G.Paganelli, C.Cacciaguerra,V.Tison5G.Landi, G. Riceputi,G.Moscatelli.M.Agostini. Istituto Oncologico Romagnolo. Servizio di Medicir.a Nucleare Ospedale M.Bufalini 47023 Cesena ITALY. As a unit of a multicenter clinical trial coordi - nated by the National Reserch Council we studied two groups of patients,in the last three years.In the first group of undred patients affected by ma- lignat melanoma with stage I-IV we were able to de tect the 75% of well documented lesions employing a 99mTC labelled F(ab')2 fragments of MoAb raised a- gainst melanoma (HMW MAA)225.28S(TECNEMAB 1-SORIN BIOMEDICA).In addition a certain number of unknown metastases were also detected and confirmed after- wards. The second group consisted of two-undred pa tients with gastro-intestinal,breast and lung carci^ noma.In these cases we used a 111 In and or 131 I labelled F(ab')i) fragments of a MoAb Raised against CEA(clone F023C5-S'?RIN-Biomedica) with best results in patients bearing colon retto carcinoma and lung cancer.More in detail we obtained the 8<~-% and the 91% of positive scans respectively.In order to im- prove the sensitivity and the tumour/BK ratio some patients with G.I.
    [Show full text]